Provided by Tiger Trade Technology Pte. Ltd.

MaxCyte Inc

1.09
-0.0300-2.68%
Post-market: 1.090.0004+0.04%17:59 EDT
Volume:397.06K
Turnover:438.13K
Market Cap:112.49M
PE:-3.27
High:1.16
Open:1.12
Low:1.08
Close:1.12
52wk High:1.87
52wk Low:0.6434
Shares:103.21M
Float Shares:92.68M
Volume Ratio:1.09
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3338
EPS(LYR):-0.4200
ROE:-20.39%
ROA:-10.64%
PB:0.71
PE(LYR):-2.60

Loading ...

MaxCyte Names Sidharth Kapileshwar Chief Corporate Development Officer

Reuters
·
Sep 23

MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer

THOMSON REUTERS
·
Sep 23

MaxCyte Grants 220,000 Stock Options, 110,000 RSUs to New Corporate Development Chief Kapileshwar

Reuters
·
Sep 12

MaxCyte Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 12

Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT)

TIPRANKS
·
Aug 24

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

GlobeNewswire
·
Aug 19

MaxCyte Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

MaxCyte Reports Q2 Results, Highlights Genentech Partnership

TIPRANKS
·
Aug 13

MaxCyte Publishes Corporate Presentation on Scalable Electroporation Platform for Cell and Gene Therapies

Reuters
·
Aug 13

MaxCyte Q2 Revenue Beats Estimates

Reuters
·
Aug 13

MaxCyte Q2 FY26 Net Loss Narrows 28% to $8.9 Million; Revenue Drops 15% to $7.3 Million

Reuters
·
Aug 13

MaxCyte Q2 EPS $(0.08) Beats $(0.09) Estimate, Sales $7.271M Beat $6.475M Estimate

Benzinga Earnings
·
Aug 13

MaxCyte Q2 Cash & Investments USD 141.9 Million

THOMSON REUTERS
·
Aug 13

MaxCyte Q2 Gross Profit USD 5.6 Million

THOMSON REUTERS
·
Aug 13

MaxCyte Q2 EPS USD -0.08

THOMSON REUTERS
·
Aug 13

MaxCyte: Full Year Revenue Expected to be $30 Million to $32 Million

THOMSON REUTERS
·
Aug 13

Press Release: MaxCyte Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 13

MaxCyte Inc Expected to Post a Loss of 9 Cents a Share - Earnings Preview

Reuters
·
Aug 11

MaxCyte Enters Technology License Partnership With Genentech

MT Newswires Live
·
Jul 21

MaxCyte enters technology license partnership with Genentech

TIPRANKS
·
Jul 21